Aclarion, Inc.
Aclarion, Inc. scores highest on Torque (66) and lowest on Nitro (10). Its PosiPenta is 38.81 out of 100, weaker than most similar companies.
On the Penta Grid this week, Aclarion, Inc. is Grid #575 of 837 in the Healthcare sector in United States, and Grid #2,993 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Aclarion, Inc. | 38.81 | 48 | 25 | 10 | 66 | 45 |
| Intelligent Bio Solutions Inc. | 28.26 | 40 | 46 | 10 | 23 | 22 |
| Traws Pharma, Inc. | 27.01 | 20 | 28 | 7 | 47 | 33 |
| Sonoma Pharmaceuticals, Inc. | 39.93 | 42 | 52 | 30 | 51 | 25 |
| Healthcare Triangle, Inc. | 34.39 | 50 | 40 | 1 | 42 | 39 |
| Mangoceuticals, Inc. | 40.24 | 45 | 49 | 20 | 49 | 37 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.25 |
| P/B ratio | 0.31 |
EEarnings
| Trailing EPS | ₹-699.00 |
| Forward EPS | ₹-518.09 |
NNitro
| Price | 175.22 |
| 52-week high | 886.53 |
| 52-week low | 175.22 |
| Fall from 52-week high | 80.2% |
TTorque
| Return on equity (ROE) | -58.97% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 1.21 |
| Market cap | ₹50 Cr |
| Insider holding | 23.98% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Aclarion, Inc.'s PosiPenta score?
Aclarion, Inc.'s PosiPenta is 38.81 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Aclarion, Inc. stand on the Penta Grid?
On the Penta Grid this week, Aclarion, Inc. is Grid #575 of 837 in the Healthcare sector in United States, and Grid #2,993 of 4,000 in United States.
Which PosiPenta pillar is strongest for Aclarion, Inc.?
Torque (durability), with a score of 66 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Aclarion, Inc.?
Nitro (momentum), with a score of 10 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.